Alvotech

Yahoo Finance • 4 days ago

ALVO INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alvotech

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Alvotech (“Alvotech” or the “Company”) (NASDAQ:ALVO) investors concerning the Company’s and/or members of its senior... Full story

Yahoo Finance • 18 days ago

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations tha... Full story

Yahoo Finance • 19 days ago

ALVO INVESTOR ALERT: Hagens Berman Investigates Alvotech (ALVO) for Potential Securities Fraud Following Massive FDA-Induced Stock Crash

SAN FRANCISCO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- National shareholder rights firm Hagens Berman is investigating Alvotech (NASDAQ: ALVO) regarding the propriety of its disclosures concerning the company’s manufacturing operations and the... Full story

Yahoo Finance • 23 days ago

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio® in healthy adult participants, met all its primary endpoints REYKJAVIK, Iceland, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alv... Full story

Yahoo Finance • 23 days ago

Alvotech kynnir jákvæða niðurstöðu rannsóknar á lyfjahvörfum AVT80, fyrirhugaðrar hliðstæðu við líftæknilyfið Entyvio

Allir endapunktar rannsóknarinnar voru uppfylltir, en hún bar saman lyfjahvörf, öryggi, þolanleika og ónæmingarverkun AVT80 og Entyvio í heilbrigðum einstaklingum Alvotech (NASDAQ: ALVO, ALVO SDB) tilkynnti í dag að jákvæð niðurstaða lægi... Full story

Yahoo Finance • 2 months ago

Alvotech Secures Term Loan Facility of USD 100 Million

USD 100 million senior term loan facility with a 2-year maturityStrengthens liquidity to support execution across Alvotech’s R&D pipeline and global product launches through 2026Led by GoldenTree Asset Management REYKJAVIK, Iceland, Dec.... Full story

Yahoo Finance • 2 months ago

Alvotech tryggir 100 milljóna dollara fjármögnun

100 milljón dollara lánsfjármögnun til tveggja áraStyrkir lausafjárstöðu og styður við áframhaldandi vöruþróun og markaðssókn út árið 2026Fjármögnunin var leidd af GoldenTree Asset Management REYKJAVÍK (31. DESEMBER 2025) - Alvotech (NASD... Full story

Yahoo Finance • 2 months ago

Alvotech’s Financial Calendar for 2026

Alvotech (NASDAQ: ALVO, ALVO SDB) today publishes its financial calendar for 2026. Annual or interim results are released on the dates specified below, after the close of U.S. markets. An investor call is held on the following day, after r... Full story

Yahoo Finance • 2 months ago

Fjárhagsdagatal Alvotech fyrir árið 2026

Meðfylgjandi er nýtt fjárhagsdagatal Alvotech (NASDAQ: ALVO, ALVO SDB) fram til fjórða ársfjórðungs 2026. Árs- eða árshlutauppgjör eru birt á viðkomandi degi, eftir lokun markaða í Bandaríkjunum. Kynningarfundur fyrir fjárfesta er haldinn... Full story

Yahoo Finance • 2 months ago

Alvotechs Finansiella Kalendar för 2026

Alvotech (NASDAQ: ALVO, ALVO SDB) offentliggör idag sin finansiella kalender för 2026. Års- eller delårsrapporter publiceras på angivet datum, efter stängning av marknaderna i USA. En investerarpresentation hålls följande dag. 18 mar 2026... Full story

Yahoo Finance • 2 months ago

Alvotech announces European launch of biosimilar to Simponi

* Alvotech (ALVO [https://seekingalpha.com/symbol/ALVO]) said on Monday that launches are underway [https://seekingalpha.com/pr/20346661-alvotech-announces-european-launch-of-first-in-market-biosimilar-to-simponi-golimumab]in Europe for... Full story

Yahoo Finance • 2 months ago

Alvotech, Teva reach settlement with Regeneron over Eylea biosimilar AVT06 in U.S.

[Chemist developing new medicine in laboratory] Luis Alvarez Alvotech (ALVO [https://seekingalpha.com/symbol/ALVO]) and Teva Pharmaceuticals (TEVA [https://seekingalpha.com/symbol/TEVA]) have reached a settlement and license agreement wit... Full story

Yahoo Finance • 2 months ago

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances REYKJAVIK, Iceland and TEL A... Full story

Yahoo Finance • 2 months ago

Alvotech og Teva ná samningi um að sala AVT06 hliðstæðunnar við Eylea má hefjast í Bandaríkjunum á fjórða ársfjórðungi 2026

Alvotech (NASDAQ: ALVO) og Teva Pharmaceuticals, bandarískt dótturfyrirtæki Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), hafa náð samningi við Regeneron Pharmaceuticals sem veitir Alvotech og Teva heimild til að markaðssetja... Full story

Yahoo Finance • 2 months ago

Bragar Eagel & Squire, P.C. Continues Investigations into Beyond Meat and Alvotech on Behalf of Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Beyond Meat, Inc. (NASDAQ:BYND) and Alvotech (NASDAQ:ALVO). Our inves... Full story

Yahoo Finance • 3 months ago

Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman

SAN FRANCISCO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over the propriety of its disclosures regarding its lead drug candidate an... Full story

Yahoo Finance • 3 months ago

European Commission Approves Alvotech's AVT03 As A Biosimilar To Prolia And Xgeva

(RTTNews) - Alvotech (ALVO) announced that the European Commission has approved AVT03, a biosimilar to Amgen's Prolia and Xgeva for use across Europe. Prolia is indicated to treat osteoporosis and bone loss in postmenopausal women and in... Full story

Yahoo Finance • 3 months ago

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

REYKJAVIK, Iceland, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Com... Full story

Yahoo Finance • 3 months ago

Markaðsleyfi veitt á Evrópska efnahagssvæðinu fyrir AVT03, hliðstæðu Alvotech við líftæknilyfin Prolia og Xgeva  

REYKJAVÍK, 25. NÓVEMBER 2025 - Alvotech (NASDAQ: ALVO) tilkynnti í dag að Framkvæmdastjórn Evrópusambandsins hafi veitt markaðsleyfi á Evrópska efnahagssvæðinu fyrir AVT03, hliðstæðu við líftæknilyfin Prolia og Xgeva, sem bæði innihalda vi... Full story

Yahoo Finance • 3 months ago

Bragar Eagel & Squire, P.C. Continues Investigations into Regencell, Beyond Meat, Alvotech, and Camping World on Behalf of Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regencell Bioscience Holdings Limited (NASDAQ:RGC), Beyond Meat, Inc.... Full story